Panmure Liberum acts as Nominated Adviser, Joint Bookrunner and Joint Broker on Arecor Therapeutics’ £6.4 million fundraise
We are pleased to announce that Panmure Liberum acted as Nominated Adviser, Joint Bookrunner and Joint Broker on a successful fundraise, raising £6.4m for Arecor Therapeutics plc.
Arecor is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products which are safer, more effective and easier-to-use, with a vision to provide improved outcomes and quality of life to patients.
The net proceeds of the fundraise will be used to drive revenue growth across the business, working capital and balance sheet strength with a view to delivering shareholder value. The fundraise will also allow the Company to continue to invest in research and development and drive sales of its Ogluo® product through investment in inventory and in awareness and marketing campaigns in the UK and Germany.
The fundraise comprised a Placing of new shares via an ABB to raise £5.2m, a direct Subscription to raise £1.0m and a Retail Offer via the Winterflood Retail Access Platform (WRAP) to raise £0.16m.
Panmure Liberum Team
Corporate Advisory – Emma Earl, Freddy Crossley, Mark Rogers, Freddie Wooding, Ivo Macdonald
Corporate Broking – Rupert Dearden, Rauf Munir
Research – Julie Simmonds
Sales – David Cox, Oliver Baxendale, Oliver Houghton, Graham Smith
CIR – Jodi Hutchins
Legal – Noth Malaba
